Lackey Melinda 4
4 · Valion Bio, Inc. · Filed May 4, 2026
Research Summary
AI-generated summary of this filing
Valion Bio (VBIO) GC Melinda Lackey Receives 45,000-Share Option Award
What Happened
- Melinda Lackey, General Counsel & SVP of Legal at Valion Bio (VBIO), was granted a derivative equity award covering 45,000 shares on 2026-05-01. The reported acquisition price/strike is $0.00, so the immediate reported cash value is $0. This is a compensation grant (award), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-05-01; Form filed: 2026-05-04.
- Shares/units granted: 45,000 (derivative award); reported price/strike: $0.00.
- Shares owned after transaction: Not reported in the Form 4 provided.
- Footnote: Vesting is 25% at the first anniversary of the grant, then the remaining 75% in 12 equal quarterly installments (rounded down), so the award is fully vested on the fourth anniversary.
- Filing timeliness: No late-filing flag indicated in the supplied details.
Context
- This is an equity compensation grant (derivative award) that vests over four years; it does not represent an immediate open-market purchase or sale. Such grants are common for employee compensation and do not by themselves indicate a personal buy or sell decision.
Insider Transaction Report
Form 4
Valion Bio, Inc.VBIO
Lackey Melinda
General Counsel & SVP of Legal
Transactions
- Award
Employee Stock Option (Right to Purchase)
[F1]2026-05-01+45,000→ 45,000 totalExercise: $0.96Exp: 2036-05-01→ Common Stock (45,000 underlying)
Footnotes (1)
- [F1]The stock option vests as follows: (i) 25% upon the first anniversary of the grant date, and (ii) the remaining 75% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date.
Signature
/s/ Melinda Lackey|2026-05-04